Engineering the Next Wave of Immunotherapy
Friday, September 17, 2021
Zoom
Please note that this year's presenter sessions were not recorded.
Cancer immunotherapy has revolutionized the landscape of cancer treatment, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy, culminating in multiple FDA-approved treatments and the awarding of the 2018 Nobel Prize in Medicine to Jim Allison and Tasuku Honjo, the field is currently at a critical juncture.
While checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer, the next generation of treatments will require us to understand what causes resistance in non-responders, how this can be overcome, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy.
Schedule
8:30-8:45
Welcome and Introduction
8:45-10:15
Targeting T Cells
Rafi Ahmed | Emory University School of Medicine | T cell lifestyle in chronic infection and cancer: implications for immunotherapy
Chris Love | Koch Institute at MIT | Single-cell clonotypic analysis of T cells
Michael Dougan | Massachusetts General Hospital; Harvard Medical School | In vivo blockade of immune regulator receptors in humans: Immunotherapy toxicities
10:30-12:30
Thinking Beyond T Cells
Lauren Zasadil | Koch Institute at MIT | Immune Clearance of Aneuploid Cells In Vivo
Yasmine Belkaid | National Institute of Allergy and Infectious Diseases, NIH | Endogenous retroviruses control of responses to the microbiota
Stefani Spranger | Koch Institute at MIT | Engaging the dendritic cell compartment to induce potent anti-tumor T cell responses
Juan Mendoza | University of Chicago | Enhancing the therapeutic potential of interferons through molecular engineering
1:30-3:00
Engineering Clinical Translation
Chris Garcia | Stanford University School of Medicine | Opening new immunotherapeutic doors at the cell surface through receptor-ligand engineering
Juliana Idoyaga | Stanford University School of Medicine | Emerging dendritic cell heterogeneity: The in-betweens
Crystal Mackall | Stanford University School of Medicine | Next generation CAR T cells to overcome resistance
3:15–4:00
Panel Discussion: Clinical Translation: A Real Life Perspective
Daniel Chen | Former Chief Medical Officer, IGM Biosciences
Michael Dougan | Gastroenterologist and Internist, Massachusetts General Hospital
Kimberly Shafer-Weaver | Global Director, GU Clinical Trial Lead, Bristol Myers Squibb
Moderators: Steven Silverstein, Chair, Melanoma Research Foundation; Jane Wilkinson, Executive Director, Koch Institute at MIT
Thank you to our sponsors:
Agilent Technologies, Inc.
Dragonfly Therapeutics, Inc.
Repertoire Immune Medicines
Ribon Therapeutics
Skyhawk Therapeutics